Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

• Published in: The lancet. Diabetes & endocrinology Vol. 12; no. 6; pp. 380 - 389
• Main Authors: Roth, Christian L, Scimia, Cecilia, Shoemaker, Ashley H, Gottschalk, Michael, Miller, Jennifer, Yuan, Guojun, Malhotra, Sonali, Abuzzahab, M Jennifer
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2024
• ISSN: 2213-8587; 2213-8595; 2213-8595
• DOI: 10.1016/S2213-8587(24)00087-1

Hypothalamic obesity resulting from hypothalamic damage might affect melanocortin signalling. We investigated the melanocortin-4 receptor agonist setmelanotide for treatment of hypothalamic obesity. This phase 2, open-label, multicentre trial was done in five centres in the USA. Eligible patients were aged between 6 and 40 years with obesity and history of hypothalamic injury or diagnosis of a non-malignant tumour affecting the hypothalamus that was treated with surgery, chemotherapy, or radiation. Setmelanotide was titrated up to a dose of 3·0 mg and administered subcutaneously once a day for a total duration of 16 weeks. The primary endpoint was the proportion of patients with a reduction in BMI of at least 5% from baseline after 16 weeks, compared with a historic control rate of less than 5% in this population. The primary endpoint was analysed using the full analysis set, which includes all patients with baseline data who received at least one dose of setmelanotide. Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT04725240) and is complete. Between June 6, 2021, and Jan 13, 2022, 19 patients were screened for inclusion. One patient was excluded, and 18 were enrolled and received at least one dose of setmelanotide. Patients were primarily White (n=14 [78%]) and male (n=11 [61%]). Enrolled patients had a mean age of 15·0 years (SD 5·3) and a mean BMI of 38·0 kg/m2 (SD 6·5). Of 18 patients enrolled, 16 (89%) of 18 patients completed the study and met the primary endpoint of reduction in BMI of at least 5% from baseline after 16 weeks (p<0·0001). The mean reduction in BMI across all patients was 15% (SD 10). A composite proportion of patients had a clinically meaningful change (89%, 90% CI 69–98%; p<0·0001), comprising a reduction in BMI Z score of at least 0·2 points for patients younger than 18 years (92%, 68–100%; p<0·0001) and reduction in bodyweight of at least 5% for patients aged 18 years or older (80%, 34–99%; p<0·0001). Patients aged 12 years or older had a mean reduction in hunger score of 45%. Frequent adverse events included nausea (61%), vomiting (33%), skin hyperpigmentation (33%), and diarrhoea (22%). Of 14 patients who continued treatment in a long-term extension study (NCT03651765), 12 completed at least 12 months of treatment at the time of publication and had a mean change in BMI of −26% (SD 12) from index trial baseline. These findings support setmelanotide as a novel effective treatment of hypothalamic obesity. Rhythm Pharmaceuticals.